Gilenya vs. Amantadine hydrochloride: side effect and effectiveness comparison (a real world drug study)
Summary:
We compare the side effects and drug effectiveness of Gilenya and Amantadine hydrochloride. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 140,500 people who take Gilenya and Amantadine hydrochloride, and is updated regularly.
What is Gilenya?
Gilenya has active ingredients of fingolimod. It is often used in multiple sclerosis. eHealthMe is studying from 111,893 Gilenya users. Check the latest studies of Gilenya.
What is Amantadine hydrochloride?
Amantadine hydrochloride has active ingredients of amantadine hydrochloride. It is often used in parkinson's disease. eHealthMe is studying from 2,398 Amantadine hydrochloride users. Check the latest studies of Amantadine hydrochloride.
140,500 people who take Gilenya and Amantadine hydrochloride are studied.
Drugs being compared in this study:
- Gilenya (fingolimod)
- Amantadine Hydrochloride (amantadine hydrochloride)
Most common side effects of the drugs, overall:
Most common side effects of the drugs, in long term (1+ years) use:
Drug effectiveness:
Gilenya:
- not at all: 2.73 %
- somewhat: 16.82 %
- moderate: 43.64 %
- high: 26.82 %
- very high: 10.0 %
Amantadine Hydrochloride:
- not at all: 5.58 %
- somewhat: 24.91 %
- moderate: 35.32 %
- high: 27.51 %
- very high: 6.69 %
Want to compare Gilenya with Amantadine hydrochloride?
- Personalize this study to your gender and age (0-99+)How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Yang Y, Teja S, Baig K, "Bilateral corneal edema associated with amantadine", Canadian Medical Association Journal, 2015 Oct .
- Alroughani R, "Fingolimod-associated amenorrhea: a report of three cases", Multiple Sclerosis Journal, 2014 Jan .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
- Cattoni J, Parekh R, "Acute respiratory distress syndrome: A rare presentation of amantadine toxicity", The American journal of case reports, 2012 Jan .
- Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
- Yang Y, Teja S, Baig K, "Bilateral corneal edema associated with amantadine", Canadian Medical Association Journal, 2015 Oct .
- Alroughani R, "Fingolimod-associated amenorrhea: a report of three cases", Multiple Sclerosis Journal, 2014 Jan .
- Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
- Cattoni J, Parekh R, "Acute respiratory distress syndrome: A rare presentation of amantadine toxicity", The American journal of case reports, 2012 Jan .
Related studies
Alternative drugs to, pros and cons of:
- Gilenya (111,638 reports)
- Amantadine hydrochloride (2,038 reports)
Browse all side effects of Gilenya:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Amantadine hydrochloride:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study is based on fingolimod and amantadine hydrochloride (the active ingredients of Gilenya and Amantadine hydrochloride, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Dimenhydrinate and Oxycodone - 4 seconds ago
- Drug interactions of Gravol and Percocet - 13 seconds ago
- Could Metoclopramide cause Intestinal Infarction? - 17 seconds ago
- Could Ancef cause Mouth Ulcers? - 42 seconds ago
- Could Aleve cause Delirium? - 44 seconds ago
- Ultram vs. Flexeril, side effect and effectiveness comparison - 51 seconds ago
- Drug interactions of Paracetamol and Fludrocortisone Acetate - 58 seconds ago
- Could Gemcitabine cause Abdominal Pain Lower? - a minute ago
- Could Arginine cause Urticaria? - a minute ago
- Yasmin vs. Desogestrel; Ethinyl, side effect and effectiveness comparison - a minute ago